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ProteaseConformational sampling of pre- and post-therapy subtype B HIV-1 protease sequences derived
from a pediatric subject infected via maternal transmission with HIV-1 were characterized by
double electron–electron resonance spectroscopy. The conformational ensemble of the PRE con-
struct resembles native-like inhibitor bound states. In contrast, the POST construct, which contains
accumulated drug-pressure selected mutations, has a predominantly semi-open conformational
ensemble, with increased populations of open-like states. The single point mutant L63P, which is
contained in PRE and POST, has decreased dynamics, particularly in the ﬂap region, and also displays
a closed-like conformation of inhibitor-bound states. These ﬁndings support our hypothesis that
secondary mutations accumulate in HIV-1 protease to shift conformational sampling to stabilize
open-like conformations, while maintaining the predominant semi-open conformation for activity.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
HIV-1 protease (HIV-1 PR) is a homodimeric aspartyl protease
that plays a fundamental role in the HIV-1 viral life cycle and
infection [1]. Speciﬁcally, this enzyme cleaves the polyproteins
gag and gag–pol into functional viral proteins necessary for mature
infections viral particles. As such, HIV-1 PR is an active target in
antiretroviral therapy [2]. Protease inhibitors (PIs) are designedas competitive inhibitors that bind within the active site cavity.
Fig. 1 shows a ribbon diagram of the structure of HIV-1 PR
highlighting the active site aspartic acid residues and the b-hairpin
‘‘ﬂaps’’ that modulate access to this pocket. HIV-1 PR is known to
undergo signiﬁcant conformational changes during the catalytic
cycle, with various mechanisms of ﬂap motion being described
for substrate and inhibitor entry, as well as product release [3,4].
We have been pioneering the usage of pulsed electron double
resonance (PELDOR), also commonly referred to as double elec-
tron–electron resonance (DEER), in combination with site-directed
spin-labeling (SDSL), to characterize the conformational sampling
of HIV-1 PR under various conditions [5–13]. DEER measures the
strength of the dipolar coupling between two electron spins, where
the coupling is proportional to r3, with r representing the
interspin distance [14,15].
Using the spin label (1-oxyl-2,2,5,5-tetramethyl-D3-pyrroline-
3-methyl) methane-thiosulfonate (MTSL) at site K55, referred to
as K55R1, distinct ensembles for HIV-1 PR have been described.
These are designated as semi-open, closed (or closed-like),
wide-open and, tucked/curled (or curled-open); where ensemble
assignments are based upon structural insights from molecular
dynamic simulations and X-ray crystallography [4,12,13,16].
Fig. 1. Ribbon diagram of HIV-1PR (PDB ID 2PBX) with ‘‘ﬂaps’’ and K55R1 reporter
sites shown in tan, active site catalytic D25 residues in purple, the hinge regions in
red, and L63 and A71 residues as green and pink; respectively.
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variants. The variants referred to as PRE and POST represent sub-
type B alleles derived from a pediatric subject before and after PI
treatment; respectively, where HIV infection was transmitted via
maternal transmission [17]. The gag–pol alleles were isolated from
serial blood samples obtained over 7 years, starting before therapy
initiation (PRE) and after the development of multiple drug resis-
tance following 77 weeks of PI therapy with Ritonavir (RTV) and
an additional 16 weeks with Indinavir (IDV) (POST) [17,18]. The
effects of the single secondary mutations, L63P, on the conforma-
tional sampling of subtype B (LAI) sequence was also investigated
because it is a common natural polymorphism contained within
the PRE sequence.
2. Materials and methods
2.1. Cloning and mutagenesis
DNA that encodes for Escherichia coli codon optimized subtype B
PRE and POST sequences were purchased from DNA 2.0 (Menlo
Park, CA). Each construct was cloned into pET-23a vector (Nova-
gen, Madison WI) under the control of a T7 promoter. The L63P
construct was generated using site-directed mutagenesis kit
(Strategene) and made within the subtype B background of a pen-
tamutated protease containing the stabilizing mutations Q7K, L33I,
L63I and substitution of native cysteines to alanine: C67A, C95A.
PRE and POST also contain the C67A and C95A mutations. All sam-
ples for DEER spectroscopy also contain the D25N mutation and
K55C for labeling. The ﬁdelity of the HIV-1 PR genes was conﬁrmed
by Sanger DNA sequencing (ICBR Genomics Facility, University of
Florida). L63P for NMR studies did not contain the K55C mutation.
All sequences are given in Table S1.
2.2. Protein expression, puriﬁcation and spin-labeling
Protein expression for EPR and NMR measurements proceeded
as described previously [5,6,12,13] with the following modiﬁca-
tions: the inclusion body resuspension buffer pH used for anion
exchange depends upon the isoelectric point of a given construct.
Buffers were adjusted to pH 9.06 for PRE and POST and pH 9.39
for L63P. For spin-labeling, MTSL dissolved in ethanol is added in
three to fourfold molar excess to protein in 10 mM Tris–HCl pH
6.9 buffer. The reaction is allowed to proceed in the dark for 6–
12 h. Excess spin-label is removed by buffer exchange into 2 mM
NaOAC pH 5.0 using HiPrep 26/10 desalting columns. Electrospraymass spectrometry results and obtained masses of labeled proteins
are given in Figs. S7–9 and Table S2.
2.3. Sample preparation, DEER data collection and analysis
For DEER spectroscopy, samples were prepared at 100 mM HIV-
1 PR homodimer in 20 mM D3-NaOAc/D2O, pH 5.0 with 30% v/v D8-
glycerol as described previously [10,12]. Details of data collection
and sample analysis have been described in detail elsewhere
[10,12,19]. Complete data analysis is given in Supporting
Information.
2.4. Sample preparation, NMR data collection and analysis
All spectra were obtained at 293 K. All 600 MHz measurements
were made on a Bruker Avance spectrometer with a 5 mm TXI
cryoprobe (AMRIS Facility, University of Florida). All 700 MHz data
were collected on a Bruker Avance system with a 5 mm TCI
700S4 h-C/N-D-05Z Cryoprobe (NHMFL facility, Department of
Chemistry and Biochemistry, Florida State University). NMRPipe
[20] and Sparky (Goddard and Kneller, Sparky 3, UCSF, San
Francisco) were used for processing and analysis of all NMR data.
Given that the L63P construct contains only one mutation com-
pared to subtype B, assignments were made based upon previously
published results [21].
Relaxation measurements were performed on 15N L63P at 600
and 700 MHz as described previously [12]. Experimental errors
for NOE values were evaluated by error propagation using reso-
nance intensity errors. Consistency of measurements performed
at different magnetic ﬁeld strengths was conﬁrmed as proposed
by Morin et al. [22]. Model-free analysis was performed using
relaxGUI (http://www.nmr-relax.com/) [23–25].3. Results and discussion
3.1. Altered conformational sampling in PRE and POST
The PRE construct differs from subtype B-LAI sequence by four
polymorphisms including S37T, P39T, I62V, and L63P, likely the
result of natural genetic drift in the mother of the infected child.
The POST construct contains 8 additional drug-selected polymor-
phisms, including L10I, I15V, E34Q (negative to uncharged),
M36I, T37N, I54A, R57E (positive to negative), and V82A. The loca-
tions of these mutations are shown in Fig. S2 and sequences given
in Table S1.
Background corrected dipolar modulated echo curves and cor-
responding TKR distance proﬁles are shown in Fig. 2A and Fig
2B; respectively. Data were analyzed with DeerAnalysis2011 [15]
and subsequent Gaussian population analysis as described in detail
elsewhere [10,12]. Full details of data analysis are given in the Sup-
porting Information. It is clear from these data that the PRE con-
struct has a most probable distance of 33 Å, which corresponds
well with a closed-like ensemble, typically seen upon addition of
inhibitors [6–9]. In contrast, a most probable distance of 37 Å is
seen for POST, similar to the most probable distance observed in
subtype C and the drug resistant construct MDR769 [9,11,13]. It
is noteworthy that both distance proﬁles differ markedly from that
of subtype B, which has a most probable distance near 35 Å. Table 1
summarizes the DEER results for these four variants.
To interrogate what residue(s) may be responsible for the shift
in conformation to a close-like state, we generated the single
mutant, L36P, which is a common natural polymorphism and a res-
idue that has been studied with molecular dynamics simulations
suggesting this site may affect the conformational ﬂexibility [26].
Results in Fig. 2 show that L63P adopts a conformation with a
Fig. 2. (A) Background corrected DEER echo curves for PRE (grey), L63P (red), A71V (blue), and POST (orange) constructs. Solid lines through data are ﬁts from Tikhonov
regularization (TKR) procedures. (B) Distance proﬁles from DEER2011, where dotted lines indicate the distances consistent with the closed-like (33 Å) and semi-open (36 Å)
populations. (C) Gaussian populations used reconstructing the TKR distance proﬁles for L63P, showing contributions from individual conformations described as curled/
tucked (black), closed-like (red), semi-open (blue), and wide-open (green). In (A) and (B), data are offset for clarity.
Table 1
Summary of distance parameters obtained from DEER distance proﬁles of HIV -1PR
constructs.
Construct Range (span)
(± 1 Å)
Most prob. dist.
(± 0.2 Å)
Avg. dist.
(± 0.2 Å)
Subtype B* 24–45 (21) 35.2 35.2
PRE 25–45 (20) 33.2 31.9
POST 27–41 (14) 37.3 34.5
L63P 31–43 (12) 33.2 34.4
A71V§ 31–43 (12) 33.0 33.2
* Data from Ref. [13].
§ Data taken from Ref. [10].
~33 Å ~36 Å
40 - 45 Å24 - 30 Å
A 
B 
Fig. 3. (A) Fractional occupancy of the closed-like, semi-open, tucked/curled and
wide-open conformations for each variant. Error is approximated at (5–8%). (B)
Models of HIV-1 PR in the various conformational poses, with the MTSL label at
position 55 shown in blue.
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observed similar results for A71V in the absence of inhibitors
[10], and those data are included here for comparison. Interest-
ingly, as discussed more below, both L63P and A71V are located
in the same region of the protein (Fig. 1) identiﬁed as a ‘‘cantilever’’
region [27,28] located near a hydrophobic cluster, which may have
important roles in modulating ﬂexibility and conformational
changes of HIV-1 PR through the hydrophobic sliding mechanism
[29].
3.2. Conformational sampling ensembles
Regeneration of the TKR distance proﬁles via linear combina-
tions of Gaussian populations provides ﬂap conformational ensem-
bles proﬁles for HIV-1 PR [10,12,13]. Fig. 2C shows the results of
the population analysis of L63P HIV-1 PR conformational sampling
based upon a Gaussian reconstruction of the data in Fig 2B. These
analyses provide details of fractional occupancy of conformers in
the ensemble; comprised of states assigned to tucked/curled,
closed-like, semi-open and wide-open conformers. Full details of
data analysis for all constructs are given in Figs. S4–6. Based upon
previous characterizations, the average distances for the preceding
populations are 24–30, 33, 35–37, and 42 Å; respectively
[4,6,12,13,16,30–33]. Shown in Fig. 3A are the relative populations
of each distinct ﬂap conformation that comprise the states in the
conformational ensemble of HIV-1PR. Pictorial models of these
states, with spin-label added in silico via MMM 2011.11 (http://
www.epr.ethz.ch/software/), are given in Fig. 3B. Models for closed
and semi-open states come from crystal structures; whereas those
for open-like and tucked/curled are from molecular dynamic sim-
ulation poses [34].
The PRE sequence adopts an ensemble with >50% fractional
occupancy of a closed-like state; a conformation typically seen
upon interaction with inhibitor. [6,8,9] Because no inhibitor was
added to these samples, we term this a closed-like conformation(in contrast to closed) because, as discussed previously [10], we
do not expect the structure to be identical to an inhibitor-bound
structure. The POST sequence, which results from the
accumulation of drug-pressure selected mutations after exposure
to antiviral treatment, adopts a conformational sampling proﬁle
with >45% fractional occupancy of the semi-open population, with
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tucked/curled conformations and an increase in the wide-open
relative population. This observation is similar to what we recently
observed for MDR769 and V6 [13] as well as for accumulating
D30N/M36I/A71V mutations, where cross drug resistance is associ-
ated with increases in open-like conformations [10].
Given the conformational ensemble for L63P resembles that of
PRE, results shows that it is not the absence of the stabilizing
mutations, namely Q7K, L33I, and L63I [35] that are present in
our subtype B constructs but not in PRE/POST, that cause the
alteration to the more closed-like state in PRE. Finally, the shift
from reported 35 Å in native subtype B to 33 Å in L63P and A71V
provides evidence that a single amino acid substitution is sufﬁcient
to cause a substantial shift in conformations of HIV-1 PR.
3.3. L63P backbone dynamics
Pulsed EPR experiments provide data regarding the population
of states. To interrogate backbone dynamics, high-resolution
transverse relaxation rate (R2), longitudinal relaxation rate (R1),
and (1H)–15N heteronuclear Nuclear Overhauser Enhancement
(hNOE) for peptide nitrogen of L63P were collected and compared
to subtype B. [3,12,21,36,37] NMR results are given in Figs. S10–12
and Table S2. The single point substitution construct was chosen
for NMR relaxation measurements because of minimal chemical
shift perturbations in the HSQC spectra relative to subtype B; thus,
resonance assignment could be easily inferred from published
HSQC data. Order parameter, S2, values, which characterize the
amplitude of motion of the amide bond and range from 0 to 1 inFig. 4. Results from NMR relaxation measurements providing (A) order parameter,
representation S2 on ribbon backbone of HIV-1 PR.increasing rigidity, were determined from model free analysis
[38–40]. Fig. 4A compares S2 values for L63P and subtype B. Differ-
ences between S2 for subtype B and L63P are given in Fig. 4B. Order
parameter values are graphically depicted on the ribbon diagrams
of HIV-1 PR in Fig. 4C. From the difference plots in Fig. 4B, one can
readily see that, on average, L63P is more rigid than subtype B. This
effect is particularly pronounced in the ﬂap region (residues 47–
55) and dimer interface. DEER results show that L63P shifts the
conformational ensemble to a more closed-like conformation with
a most probable distance of 33 Å. The NMR measurements indi-
cate that the overall ﬂexibility of the closed-like state is more rigid
than the semi-open conformation. Comparison of our L63P S2 val-
ues to published results on inhibitor-bound dynamics of subtype B
[3,37] shows greater ﬂexibility compared to the inhibitor-bound
closed conformation.
3.4. Effects of single point mutation L63P on conformational ensemble
and comparison to A71V
Both L63P and A71V are located away from the active site cavity
(Fig. 1) in a region of the protein that has been deﬁned by MD
simulations as a ‘‘cantilever’’ (residues 59–75), which has anti-
correlated motion with the ﬂaps [27] and where mutations in this
region are predicted from MD simulations to alter dynamics and
ﬂexibility [26,41]. L63P is a substitution within the PRE sequence
and our results show that this single point mutation may account
for the more closed-like conformation of the PRE construct; an
ensemble we have seen previously for A71V [10], with decreased
ﬂexibility. A71V is a common secondary mutation seen inS2, values for L63P (B) and differences compared to subtype B. (C) Graphical
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mutation stabilizes the dimer when primary mutations arise
[41,44].
Structurally, 63 and 71 are in close contact with residues 62, 64,
66, 89 and 93 (Fig. S13), deﬁned as being within the hydrophobic
core [29]. In crystal structures of consensus subtype B, A71 has a
side-chain that protrudes into the hydrophobic packing region;
hence the substitution with the larger valine residue may impact
the communication between the ﬂap and cantilever domain. A
recent structure of PR20 [45], a highly resistant construct that
contains A71V and L63P, shows similar packing of these residues
compared to WT. Although PR20 does not crystallize in a closed
ﬂap orientation in the absence of inhibitor, this construct also con-
tains the following mutations considered to be within the hydro-
phobic core: L10F/I13V/I15V/I33F/M36I/-I62V/L90M. Comparing
structures reveals a slight rotation of the side chain of I64 and
change in side chain of I62V (Fig. S13). L90M may also participate
in subtle changes in hydrophobic packing of this region. Interest-
ingly, the POST sequence contains hydrophobic core mutations
L10I/I15V/M36I, which are mutated positions shared by PR20.
Recently, we showed by DEER studies that addition of M36I/
D30N to A71V restores a predominant semi-open conformation
with additional ﬂap curling and open-like states [10]; conforma-
tions seen in crystal structures of PR20 [45]. To our knowledge,
no crystal structures for single mutations A71V/L63P or PRE/POST
sequence exist to date; but it is likely that substitution at these
sites may alter the hydrophobic packing in this region, thus
providing the molecular level reason for the altered ﬂexibility
and conformational sampling.
3.5. Relationship of conformational sampling, drug resistance and
enzymatic activity
The conformational ensemble of PRE, giving a predominantly
closed-like conformation, was unexpected because, except for
A71V, a ligand-free construct with a most probable distance
corresponding with the inhibitor induced closed ﬂap conformation
has not been reported. X-ray crystal structures of ligand-free HIV-1
PR primarily exhibit the semi-open conformation [4], and previous
DEER studies have shown that apo subtypes B, C, CRF01_A/E, F and
multi-drug resistant constructs V6 and MDR769 exhibit predomi-
nantly semi-open conformational states [13].
Inhibitor-bound HIV-1PR has been shown to primarily adopt
the closed conformation, caused at least in part by interaction
between the Ile50/500 amide group and ligand via a conserved
H2O [6–9,16,46]. Intra-ﬂap hydrogen bonding, which may stabilize
the closed ﬂap conformation, has been observed in MD simulations
of apo enzymes, demonstrating that the average ﬂap distance in
the closed state is similar for ligand-bound and unbound protease
[16]. This supports our experimental ﬁndings that despite having
no ﬂap-inhibitor interactions, ligand-free protease may adopt a
closed-like conformation.
Kinetic studies of A71V suggest that stabilization of the closed-
like state lowers catalytic turnover rate [10,42]. In parallel, the
work of Clemente et al. also showed minimal impact of the A71V
mutation on Ki values for Ritonavir, Indinavir and Nelﬁnavir
compared to WT [42]. Although the drug-pressure selected
mutations in POST compared to PRE were shown to affect replica-
tive ﬁtness and drug-response [17]; to date, in vitro kinetic or
inhibition studies exists for comparison to our DEER data.
Recent work from our labs has showed that correlations exist
among conformational sampling and enzymatic parameters and
inhibition constants [10]. Results from that study indicate that
drug resistance correlates with higher percentages of open-like
conformations where stabilization of the closed-like state impairs
enzymatic activity. These ﬁndings suggest a mechanism for howmutations combine; they maintain wild-type occupancy of the
semi-open conformation while increasing the population of the
open-like states and destabilizing the closed conformation. The
work reported here adds to our growing understanding of how nat-
ural polymorphisms and drug-pressure selected mutations alter
conformational sampling of HIV-1 PR, which may be communi-
cated through subtle changes in the hydrophobic packing of key
residues implicated in the hydrophobic sliding mechanism [29].
4. Conclusions
Taken together, these results add evidence to support our
hypothesis that a role of combined drug pressure selected muta-
tions may be to stabilize the semi-open conformation and induce
a larger percentage of open-like states [10]. This work shows that
drug-induced mutations, even single mutations distal to the active
site pocket, can alter conformational sampling of HIV-1PR, which
may impact drug-resistance and viral efﬁcacy. The results indicate
a possible mechanism for combining primary and secondary muta-
tions to affect the conformational ensemble equilibria. Note that
results from DEER experiments do not provide information regard-
ing ﬂexibility. NMR investigations of L63P clearly demonstrate
decreased ﬂexibility of this construct. Solution NMR assignments
and relaxation experiments are underway for PRE and POST
constructs.
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